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Background: Asthma is a chronic inflammatory airway disorder known to involve the peripheral
airways. Current guidelines state that diagnosis and treatment should be guided by symptoms
and spirometry. FEV1 is, however, a poor marker of small airway function and correlates poorly
with asthma control and airway inflammation.
Aims: To assess the contribution of small airway dysfunction and inflammation in paediatric
asthma. A secondary aim was to study the associations between small airway dysfunction,
airway inflammation and airway hyper-responsiveness (AHR).
Methods: Small airway function was measured as LCI, Scond and Sacin, evaluated with the SF6
multiple breath inert gas washout (MBW) technique, in 47 asthmatic children and 74 healthy
controls. Exhaled NO at multiple exhalation flow rates including 50 mL/s (FENO50) was assessed
to calculate alveolar NO and bronchial NO flux (a surrogate for airway inflammation). AHR was
evaluated with isocapnoic dry air hyperventilation challenge in the asthmatic children.
Results: Scond was elevated in 31 (66%) and Sacin in 18 (38%) of the asthmatic subjects. LCI was
increased and FEV1 decreased in 7 (15%) of the subjects with asthma. Individuals with AHR had
higher Scond (pZ 0.001) and FENO50 (p < 0.0001) than those without AHR. The levels of FENO50
and bronchial NO flux were elevated in asthmatic subjects compared with healthy controls. In
asthma, Scond correlated with FENO50 (rs Z 0.42, p Z 0.003) and alveolar NO (rs Z 0.40,
p Z 0.011), and Sacin correlated with alveolar NO (rs Z 0.40, p Z 0.015).sponsiveness; ACT, Asthma Control Test; ATS, American Thoracic Society; cACT, childhood Asthma
ncentration; DNO, bronchial NO diffusion capacity; ERS, European Respiratory Society; FENO, fraction
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Paediatric asthma 1477Conclusion: Dysfunction of small conducting airways is associated with airway inflammation
and hyper-responsiveness in paediatric asthma.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Asthma is a common chronic disease in childhood and
accounts for a large proportion of paediatric hospital-
isations, health care visits and absenteeism from day care
and school.1 Asthma is an inflammatory airway disorder
that involves also the peripheral airways.2e8 Current
guidelines recommend diagnosis and treatment based on
symptoms and spirometry.2 There is, however, often little
or no correlation between symptoms and airway inflam-
mation or between airway inflammation and airway
obstruction measured by spirometry.9e11 Many children do
not achieve sufficient asthma control in spite of the avail-
ability of efficient drugs.1 Lack of adherence to prescribed
therapy is a major factor but peripheral airway dysfunction
and inflammation could contribute to failed asthma
control.1,8 Access to safe, patient-friendly, non-invasive
investigations sensitive to peripheral airway function and
inflammation is therefore of high priority.
Fraction of exhaled nitric oxide (FENO) is often elevated
in subjects with asthma. FENO has been proposed as
a marker of airway inflammation in asthma and a tool for
guidance in asthma therapy.12e15 Mathematical models of
NO dynamics suggest that peripheral (alveolar) and prox-
imal (bronchial) contributions to the exhaled NO concen-
tration can be calculated on the basis of exhaled NO
measurements at multiple exhalation flow rates.13e15
Conventional spirometry is not sensitive enough to
detect pathology in the small airways.16,17 The lung clear-
ance index (LCI), derived from multiple breath inert gas
washout (MBW), measures overall ventilation inhomoge-
neity. LCI has a narrow normal range, and it is largely
independent of age.18,19 LCI has been shown to be a sensi-
tive marker of early airway disease in children with asthma
and cystic fibrosis (CF).20,21 Analysis of the progression of
the phase III (alveolar phase) slope generated during MBW
may provide even more detailed information on where
along the airway tree the ventilation inhomogeneity has
arisen.22e24 This method is based on the understanding that
a raised phase III slope requires differences in specific
ventilation and sequential filling and emptying between
lung units sharing branch points in the conducting airway
zone, or a “Pendelluft” phenomenon, occurring in the zone
of the entrance to the acinus, due to interaction between
convection and diffusion of the inert gas. Analysing the
evolution of the phase III slope from each breath during the
MBW enables the determination of the relative contribution
of these two mechanisms. Verbanck and co-workers intro-
duced Scond, and Sacin as clinical indices of ventilation
inhomogeneity.25 Scond is based on the contribution to
phase III slope from differences in ventilation distribution
occurring in the conducting airway zone. Sacin is based on
the contribution from ventilation distribution differences
generated in or close to the acinar zone. There are several
reports of elevated Sacin in adults with severe asthma, and
elevated Scond in mild to moderate asthma.
25e27Others have found an association between ventilation
inhomogeneity and NO parameters in asthma in adults.26e29
The relationships between ventilation inhomogeneity, NO
parameters and airway hyper-responsiveness in paediatric
asthma, however, remains to be established.
The primary objective of this cross-sectional study was
to assess the contribution of small airway dysfunction and
inflammation in paediatric asthma. The aim was also to
analyse the association between LCI, Scond, and Sacin,
reflecting airway dysfunction, and the NO parameters,
indicating airway inflammation, at different depths in the
airway tree. A second objective was to assess to what
extent airway inflammation and small airway dysfunction
are associated with airway hyper-responsiveness.
Material and methods
Patient characteristics
Forty-seven children (6e18 years old) with physician-
diagnosed asthma and a positive allergy test (skin prick
test for common inhalant allergens or Phadiatop test,
Phadia, Uppsala, Sweden) were enrolled in this study.
Asthma was defined according to current guidelines based
on clinical symptoms of asthma and demonstrated revers-
ible airway obstruction or a positive bronchial challenge
test.2 The Phadiatop test determines the presence of
raised specific serum IgE antibodies to common inhaled
allergens (dog, cat, horse, timothy, birch, mugwort, house
dust mite, and the mould Cladosporium) and the test result
is expressed as positive or negative with a cut-off of
0.35 kU/l of any specific IgE. The asthmatic subjects were
prescribed regular treatment with inhaled corticosteroids
(budesonide, fluticasone or mometasone 50e500 ug/day),
long- and/or short acting b2 agonists or montelukast, alone
or in combination as required (Table.1).
Controls
Seventy-four healthy children and adolescents (7e19 years
old) without a history of respiratory problems or prolonged
airway infections, were recruited from nearby schools as
healthy controls. Children with positive Phadiatop test
but without ongoing clinical allergy were included and 16 of
the 35 healthy controls who performed the NO tests had
a positive Phadiatop test (Table 2).
All the participants were never smokers, free of signs of
recent or ongoing respiratory tract infection.
Clinical characteristics of all subjects are shown in
Table 1.
Clinical examinations
Asthmatic subjects underwent, in the following order,
Table 1 Characteristics and baseline measurements of study subjects. Values are presented as mean (SD) or number
(percentage).
Controls (n Z 74) Asthma (n Z 47)
Age, years 13.6 (3.2) 13.2 (3.0)
Sex, Female/Male 36/38 12/35
Height, cm 160 (16) 159 (15)
ACT score < 20, n (%) n.a. 17 (38)a
Current asthma controller medication
Inhaled corticosteroids, n (%) 0 37 (79)b
Montelukast, n (%) 0 7 (21)c
FVC, % predicted 102 (11) 100 (10)
FEV1, % predicted 101 (11) 92 (12)
d
MMEF, % predicted 99 (21) 74 (22)d
FEV1/FVC, % predicted 98 (6) 96 (8)
d
ACTZ Asthma Control Test; ICSZ inhaled corticosteroids; LABAZ long acting b2 agonist; FVCZ forced vital capacity; FEV1Z forced
expiratory volume in 1 s; MMEF Z maximum midexpiratory flow, n.a Z not applicable.
a Missing data for three subjects.
b 23 subjects (49%) had ICS in combination with LABA.
c 6 of these subjects had concomitant treatment with ICS.
d p < 0.001 between subjects with asthma and healthy controls.
1478 C. Keen et al.(1) Phadiatop test,
(2) Asthma Control Test (ACT),
(3) exhaled NO at different exhalation flows,
(4) MBW,
(5) spirometry prechallenge,
(6) isocapnoic dry air hyperventilation challenge, and
(7) post-bronchodilator spirometry.
The healthy controls were examined with allergy test,
exhaled NO, MBW and spirometry.
Asthma Control Test (ACT)
The subjective degree of current asthma control was
assessed using the Asthma Control Test (ACT) and, for
children below 12 years of age, the childhood ACT (cACT).
ACT is a five-item assessment tool completed by the subject
with asthma designed to identify subjects whose asthma is
inadequately controlled. The score ranges from zero to 25
with higher scores indicating better asthma control. A score
of 19 or less indicates inadequately controlled asthma.30
cACT, a seven-item assessment tool completed by the
child and parent/caregiver, is similarly designed to identify
children 4e11 years of age whose asthma is inadequatelyTable 2 Exhaled NO variables in asthmatic and control subject
Positive Phadiatop, n (%)
FENO50 [ppb], median (range)
Alveolar NO, [ppb], median (range)
Bronchial NO flux, [pL/s], median (range)
Bronchial wall NO concentration, [ppb], median (range)
Bronchial NO diffusion capacity, [nL/s], median (range)
FENO Z fraction of exhaled nitric oxide; NO Z nitric oxide.
a p < 0.05 between subjects with asthma and healthy controls.controlled. The score ranges from zero to 27 and, just as for
ACT, a score of 19 or less indicates inadequately controlled
asthma.31 ACT and cACT are translated and validated into
many different languages. The Swedish versions of ACT and
cACTwere filled in by the subjects and for the cACT also the
parents and if needed for the younger children, further
explained by a nurse. The number of subjects who scored
19 or less was reported.
Measurements of exhaled nitric oxide
Exhaled NO was measured online with a chemiluminescence
analyser (ANALYZER CLD 88 AM; Eco Medics AG, Duernten,
Switzerland) with a detection limit of 0.1 ppb, in accor-
dance with the ATS/ERS recommendation.12 Exhaled NO
was measured at different expiratory flows: 30, 50, 100,
150, 200, 250 mL/s and, in some individuals, 300 mL/s.
Reported values are the mean concentrations calculated
from three measurements that agree within 10%.
Flow independent NO parameters
Alveolar NO and bronchial NO flux were calculated
according to the two-compartment model,15 where FENOs.
Controls (n Z 35) Asthma (n Z 47)
16 (43) 47 (100)
12.4 (5.2e40.1) 22.3 (4.8e184)a
1.4 (0.1e3.6) 1.2 (-1e6.1)
664 (127e2310) 1217 (155e12 139)a
43.4 (9.3e496) 84.0 (11.7e696.3)a
15.0 (1.0e51.9) 23.4 (0.6e254.4)




1 eDNO=vþCalv  eDNO=v :
Calv is the alveolar NO concentration, reflecting NO from
the most peripheral part of the airways. Cw is the bronchial
wall NO concentration, v is the flow rate and DNO is the
bronchial wall NO diffusion capacity. Cw and DNO together
represent the maximum bronchial NO flux, reflecting NO
from the bronchial compartment of the airways. All
parameters above were calculated with the so-called non-
linear method according to Ho¨gman et al.14
Multiple breath inert gas washout (MBW)
MBW was performed in triplicate as previously described.21
Briefly, all patients used a nose clip and they breathed
through a Fleisch no.1 pneumotachometer (PNT) (Metabo
SA, Lausanne, Switzerland) via a mouthpiece. The PNT was
connected to a differential pressure transducer (Validyne
Corp, CA, USA) and the signal was demodulated and
amplified (Validyne MCI-10, Validyne Corp, Northridge, Ca.,
USA). The sampling line from a respiratory mass spec-
trometer (AMIS 2000, Innovision A/S, Odense, Denmark)
was inserted between the mouthpiece and the PNT. All
respiratory gases were recorded at 33 Hz. During the wash-
in phase the patients inspired a dry gas mix containing 4%
sulphur hexafluoride (SF6), 4% helium, 21% oxygen and
balance nitrogen, using a by-pass flow system. Wash-in was
continued until the inspiratory and expiratory SF6 concen-
trations were equal and stable, plus an additional 30 s. The
by-pass flow was then disconnected during exhalation and
the washout was started. The washout phase continued
until end-tidal SF6 concentration was below 0.1% (1/40
th of
the starting concentration). For a more detailed description
of the MBW analysis, see the online supplement. LCI was
calculated as the number of lung volume turnovers required
to reduce the end-tidal SF6 concentration to less than 1/
40th of the starting concentration. Three recordings for LCI
were obtained from all children and the mean LCI was
reported.
The phase III slope of each breath during MBW was
analysed to calculate Scond and Sacin. In order to compare
phase III slopes from subsequent breaths, the effect of the
dilution of the marker gas was corrected for by dividing the
slope by the mean gas concentration over the slope,
resulting in the concentration-normalised phase III slope
(SnIII). The SnIII was multiplied by tidal volume (VT) giving
the SnIII*VT, in order to account for inter individual differ-
ences in lung size and breathing pattern.32 The SnIII)VT was
used for all subsequent analyses and is subsequently
referred to as SnIII. SnIII for each breath was then plotted
against the corresponding lung volume turnover for each
breath. Scond is defined as the rate of SnIII increase between
lung volume turnovers 1.5 and 6.0. Sacin is defined as the
first breath SnIII value minus the convection-dependent
inhomogeneity contribution to this value and Sacin consti-
tutes the diffusion-convection interaction-dependent
inhomogeneity contribution to the SnIII of the first washout
breath. Quality control criteria for SnIII analysis included
regular breathing with a tidal volume of 10e15 mL/kg bodyweight. Scond and Sacin are only reported from those indi-
viduals who fulfilled the quality control criteria and several
of the controls did not manage to do so, while all asthma
patients fulfilled the quality criteria.
Spirometry
Spirometry was performed according to American Thoracic
Society (ATS)/European Respiratory Society (ERS) stan-
dards, using a Jaeger Masterscope spirometer (Erich Jaeger
AG, Wu¨rzburg, Germany).33 Results were expressed as
percentage of predicted values using the new global “all
ages” reference values recently presented by Stanojevic
et al.34
Bronchial challenge
Bronchial challenge was performed after the baseline lung
function test (triplicate spirometry) and the asthmatic
subjects were coached to hyperventilate dry air (containing
5% CO2) at room temperature for 4 min at 75% of maximum
voluntary ventilation (26  baseline FEV1) guided by
a target balloon (Aiolos Astma Test, Aiolos Medicinsk
teknik, Karlstad, Sweden). Spirometry was repeated in
duplicates at 2, 5 and 10 min post challenge, and the
highest value at each time was used for evaluation. The
response was measured as the maximum percentage fall in
FEV1, and AHR was defined as present if the maximum fall
in FEV1 was greater than or equal to 10%. The bronchodi-
lator response was measured as the percentage rise in FEV1
from baseline after inhalation of four puffs of salbutamol
(0.1 mg/dose) from a metred dose inhaler via an anti-static
holding chamber. Short acting bronchodilator treatment
was withheld for 12 h prior to testing and long acting
bronchodilators, inhaled corticosteroids and montelukast
were withheld for 24 h.
Ethics
The study was approved by the Ethics Committee of the
University of Gothenburg. Informed consent was obtained
from all patients and controls and their parents.
Statistical analysis
The statistical analyses were performed with the SPSS
software package, version 15 (Chicago, IL, USA). Non-
parametric tests were used as the distributions of NO
parameters were skewed. Data are presented as median
and range or mean and standard deviation (SD) if not
otherwise stated. Comparisons between groups were per-
formed using ManneWhitney’s U-test or Student’s T-test if
data was not skewed. Nominal data were compared using
the Yates corrected Chi2 test. Possible relationships
between different variables were evaluated using univar-
iate analysis (Spearman’s rank correlation) and multiple
regression tests. The two-tailed significance level was set
at p < 0.05. Upper limit of normal (ULN) for LCI, Scond and
Sacin was calculated as mean þ 1.96 SD for reference
population (healthy controls).
Figure 1 (a) Scond (SF6) corrected for tidal volume and (b) Sacin (SF6) corrected for tidal volume in children with asthma and
healthy controls. Mean values are indicated for each group.
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The asthmatic subjects underwent all the clinical exami-
nations and all of the healthy controls were examined with
MBW and spirometry while allergy test and exhaled NO
were performed in 35 of the healthy controls.
Exhaled NO
FENO50, bronchial wall NO concentration and bronchial NO
flux were significantly elevated in the asthmatic subjects
compared to the controls, while alveolar NO and bronchial
NO diffusion capacity did not differ between the two groups
(Table 2).
Bronchial NO flux correlated closely with FENO50 in the
subjects with asthma (rs Z 0.97, p Z 0.0001) as well as in
healthy controls (rs Z 0.90, p Z 0.0001). Alveolar NO
showed no correlation with FENO50 in children with asthma
(rs Z 0.18, p Z 0.27) or in healthy children (rs Z 0.03,
p Z 0.87). Hence, we only present data on FENO50 and
alveolar NO in association with lung function.
There were no differences in NO variables between the
healthy controls with vs without evidence of allergic
sensitisation.
MBW
Scond and Sacin were significantly elevated (Fig. 1) and LCI
was marginally but significantly elevated in the asthmaTable 3 Results of multiple breath inert gas washout, and isoc
LCI, mean (SD)
Scond, Vt corrected, mean (SD)
Sacin, Vt corrected, mean (SD)
FEV1 max fall, %, median (range)
AHR, FEV1 fall > 10%, n (%)
Bronchodilator response, [% FEV1, change], median (range)
FEV1Z forced expiratory volume in 1 s; LCIZ lung clearance index; S
Vt Z corrected for tidal volume; AHR Z airway hyper-responsivenes
a n Z 74.
b p Z 0.001 between subjects with asthma and healthy controls.
c p Z 0.0001 between subjects with asthma and healthy controls.group compared to the controls (Table 3). The most
common abnormality in asthma was a raised Scond (66% of
the asthmatic children had values above the upper limit of
normal; ULN), followed by Sacin (38%), while only 7 (15%)
showed a raised LCI. Seven subjects with asthma had FEV1
below the lower limit of normal, see table in online
supplement (Table S1). Out of the 40 asthmatic children
with normal LCI and FEV1, 50% had elevated Scond and 25%
had elevated Sacin (See Fig S1a and S1b in online supple-
ment). There were no associations between age and LCI,
Scond or Sacin in the asthmatic subjects or the healthy
controls.
Children with uncontrolled asthma based on ACT score
(ACT score < 20) had significantly higher LCI (pZ 0.04) and
Scond (p Z 0.04) than those with well controlled asthma,
while, on average, FEV1 did not differ between subjects
with controlled and uncontrolled asthma.Associations between exhaled NO, small airway
function and airway hyper-responsiveness in
asthma
Asthmatics with a positive isocapnoic dry air hyperventila-
tion challenge test, defined as maximum FEV1 fall 10%
after challenge (n Z 20), demonstrated on average higher
FENO50 (Fig. 2a) and Scond (Fig. 2b), than those with
a negative challenge finding. In contrast, Sacin (p Z 0.23)
and alveolar NO (pZ 0.94) did not differ between subjects
with or without AHR.apnoic dry air hyperventilation challenge.
Controls (n Z 36) Asthma (n Z 47)
6.07 (0.35)a 6.44 (0.63)c
0.017 (0.004) 0.032 (0.018)c




cond, SacinZ phase III slope of the conducting and acinar airways;
s; n.a. Z not applicable.
Figure 2 (a) FENO50 and (b) Scond (SF6) corrected for tidal volume in children with asthma without airway hyper-responsiveness
(AHR) (maximum fall in FEV1 < 10%) and with AHR (maximum fall in FEV1  10%). Median is indicated for FENO50 and mean is
indicated for Scond.
Paediatric asthma 1481There were significant correlations between FENO50 and
Scond (p Z 0.003) (Fig. 3a), and FENO50 and max FEV1 fall
after dry air challenge test (p Z 0.0001) (Fig. 3b). For all
correlations, see the online supplement (Table S2). Alveolar
NO correlated with Scond (rs Z 0.40, p Z 0.011), and Sacin
(rs Z 0.40, p Z 0.015). Calculated alveolar NO rendered
negative values in four of the asthmatic subjects, all whom
had FENO50 above 100 ppb, and these subjects were not
included in the correlation tests. There was no significant
correlation between FEV1 and the NO parameters or
between FEV1 and Scond or Sacin.
Multiple regression models in the asthmatic children,
controlling for FEV1 % predicted at baseline, showed that
maximum fall in FEV1 after dry air challenge was signifi-
cantly associated with both Scond and FENO50 (Table 4).
FENO50 and Scond were evaluated in two separate models
since these variables are too closely correlated to be
included in the same model. Gender, use of inhaled corti-
costeroids and age or height were not significant contrib-
utors in these models.
There were no correlations between exhaled NO and
lung function in the healthy controls.Discussion
This study for the first time shows that a majority of chil-
dren with allergic asthma have elevated Scond and thatFigure 3 Exhaled nitric oxide (FENO50 ppb) in subjects with ast
responsiveness (maximum fall in FEV1 after isocapnoic dry air hypeelevated Scond is correlated with increased levels of FENO50
and with the presence of AHR. This study thus provides
evidence that the small conducting airways are a major site
of the disease process in children with allergic asthma. In
addition, the acinar airways are affected in about one third
of the asthmatic children in this study, suggesting that
asthma also involves very peripherally located airways, as
shown by the elevated Sacin index. Levels of Sacin are
correlated with alveolar NO but not with AHR. LCI is on
average increased in asthma, but LCI can not be used to
separate asthmatic from healthy control subjects since only
seven of the asthmatic children in this study have elevated
levels. Our findings show that the functional impairments at
different depths of the airway tree in paediatric asthma,
are associated with airway inflammation as measured with
exhaled NO dervived from the same airway location and
reside mainly in the small conducting airways.
The present study confirm the findings by Sonnapppa
et al. who recently showed that Scond was the most sensitive
marker of abnormal pulmonary function in preschool multi-
trigger wheezers.35 They reported that Scond was increased
in 68% of the children with multiple trigger wheeze
compared to healthy controls. Our study also confirms and
extends the finding of residual small airway disease in
asthmatic children reported by Macleod et al.20 LCI is
increased in both studies but in the present study, we
demonstrate that it is in the small conducting airways that
the major pathology is present. FENO50 is increased in thehma in relation to (a) Scond, rs Z 0.42, p Z 0.003, (b) airway
rventilation challenge), rs Z 0.62, p Z 0.0001.
Table 4 Two multiple regression models in subjects with asthma. The maximum fall in FEV1 after isocapnoic dry air hyper-
ventilation challenge is the dependent variable in both models.
r2 b 95% CI for b p-value
Model 1 0.560 0.0001
Constant 36.04 9.32 to 62.76 0.016
FENO50, ppb 0.255 0.143 to 0.366 0.0001
Baseline FEV1 % predicted 0.321 0.590 to (0.052) 0.021
Model 2 0.421 0.0001
Constant 43.80 12.59 to 75.01 0.007
Scond,Vt corrected 342.13 97.28 to 586.97 0.008
Baseline FEV1 % predicted 0.45 0.74 to 0.15 0.004
FENO Z fraction of exhaled nitric oxide; FEV1 Z forced expiratory volume in 1 s; Scond, Vt corrected Z index of small conducting
airway dysfunction.
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them being treated with inhaled corticosteroids, while
Macleod et al. reported normal levels of FENO50 in the
asthmatic children. The children in the Macleod study are
younger than the children in the present study, they are all
treated with ICS and 42% of the children in the Macleod
study are non atopic, which could influence the results. The
results from the present study are in consonance with data
from a study in atopic adults with mild asthma presented by
Battaglia et al., showing a correlation between exhaled NO
and overall ventilation inhomogeneity.26 Verbanck et al.,
however, found signs of abnormal function in the con-
ducting airways that was only poorly associated with
bronchial NO in adults with asthma.28 Downie et al.
recently reported that ventilation inhomogeneity arising in
the small conducting airways is a major determinant of AHR
in adults with asthma, irrespective of airway inflammation,
as measured with exhaled NO.27 In the present study there
is a clear association between dysfunction in the conduct-
ing airways, exhaled NO and AHR in the asthmatic children.
This suggests that eosinophilic airway inflammation is
a more important determinant of small airway dysfunction
and AHR in asthmatic children than in adults. In adults,
neutrophilic inflammation or airway remodelling and other
structural changes could play a greater role. There are
individuals also in the present study showing signs of small
airway disease with normal levels of FENO50 and no
evidence of AHR, indicating that the functional changes in
the small airways can occur without the presence of
ongoing allergic airway inflammation. One could speculate
that this is a sign of early airway remodelling, since others
have shown that elevations of Scond or LCI are not fully
reversible after acute treatment with b2 agonist or long-
term treatment with inhaled corticosteroids.20,28 In the
present study, there are three individuals with signs of AHR
but no concurrent elevation of FENO50, showing that AHR
can occur without concomitant allergic airway inflamma-
tion. Monitoring asthmatic children with an indirect chal-
lenge test, MBW and exhaled NO thus seems to tease out
different asthma phenotypes, which could possibly benefit
from different types of pharmacotherapy.
Large airway obstruction, as reflected by FEV1, the most
commonly used lung functionparameter in the asthmaclinic,
is not correlated with FENO50, Scond or the ACT score, adding
moreevidence for thewell-knownweak correlation between
FEV1, asthma symptoms and airway inflammation.
10,11Flow independent NO parameters
Bronchial NO flux is closely correlated with FENO50, and
these two parameters show the same correlations with the
lung function variables. Bronchial NO flux in addition to
FENO50 therefore adds little extra information. Alveolar NO
and FENO50 are not correlated, but subjects with very high
FENO50 are difficult to fit into the flow-independent
models. As a result, four of the asthmatic subjects with
FENO50 > 100 ppb demonstrated negative calculated alve-
olar NO values. Shelley et al., suggested that this could be
explained by patchy ventilation inhomogeneity and they
proposed a multi-compartment model as opposed to the
two-compartment model used in this study, for NO model-
ling.36 This multi-compartment model produced much
higher alveolar NO in some individuals, suggestive of
regional high NO production in the small airways.
The present study is an explorative cross-sectional study
including a limited number of patients. The results must,
therefore be interpreted with some caution, however, the
main findings of evidence of small airway dysfunction
associated with airway inflammation are evident despite
current inhaled corticosteroid therapy in the majority of
the asthmatic subjects. Many of the healthy children had
difficulty performing the MBW well enough to allow calcu-
lation of Scond and Sacin. However, Scond and Sacin calculated
in those healthy children who fulfilled the quality criteria
(n Z 36) were very similar to published data from adoles-
cents using the same method.37Conclusions
This study provides further evidence of small airway
involvement in paediatric asthma. The findings of clinically
significant dysfunction of the small conducting airways in
paediatric asthma and its associations with increased levels
of exhaled NO are novel, and thus provide new insights into
the pathophysiology of paediatric asthma. Exhaled NO and
MBW in combination may be useful tools when evaluating
the utility of new therapies for asthma in children. Models
for determining NO from the peripheral airways might add
new information, but the current models need further
development before they are used in children with allergic
asthma.
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